Shared contribution
INTRODUCTION 27 The rising rates of obesity are a global health epidemic. In the US alone, by 2030 it is 28 predicted that 86% of adults will be overweight or obese (1). Comorbidities include impaired 29 time of day (P < 0.001) and the interaction between day of study and time of day (P = 0.001): 95 the initial dose of mirabegron on Day 1 increased REE by 10.7% (+6.4 ± 1.2 kcal/h, P < 0.001), 96 yet the Day 28 dose of mirabegron did not further increase REE above the Day 28 pre-dose 97 baseline (0.8% = 0.5 ± 1.2 kcal/h, P = 0.70). However, the baseline REE (at 08:00) on Day 28 98 was 5.8% higher than baseline REE prior to drug exposure on Day 1 (+82 kcal/d, P = 0.01). 99 The respiratory quotient (RQ) reflects substrate source. The acute dose of mirabegron on 100 both Day 1 and Day 28, lowered the RQ (-0.069 ± 0.007 and -0.051 ± 0.007, respectively; both P 101 < 0.001) ( Figure 4B and Supplemental Table 3 ), indicating a net increase in fat oxidation. In 102 contrast to the results with REE, the baseline RQ on Day 28 was not different from Day 1 (P = 103 0.15), and the P value for the interaction between day of study and time of day was higher (P = 104 0.06). These changes in REE and RQ were likely due to both prolonged fasting and mirabegron 105 itself, but the lack of a placebo group precludes us from determining the contributions from each. 106 We also measured the energy expenditure and RQ for the entire chamber stay, from evening until 107 the next afternoon, and saw no difference in either parameter: 74.4 ± 8.4 kcal/h to 75.0 ± 8.0 108 kcal/h (P = 0.57) and 0.850 ± 0.023 to 0.854 ± 0.025 (P = 0.51), respectively. There were also 109 no changes in total sleep time or sleep efficiency: 391.8 ± 76.6 minutes to 354.5 ± 65.3 minutes 110 (P = 0.11), and 89.8 ± 8.0% to 91.5 ± 4.6% (P = 0.27), respectively. In addition, average core 111 temperature was 0.11 ± 0.02 °C higher on Day 28 (Supplemental Figure 5) . 112 A concern related to chronic treatment with adrenergic agonists is pathologic overstimulation 113 of the cardiovascular system. Here, resting heart rate (HR), systolic blood pressure (SBP), and Table 4 ). Given that there is no published evidence yet to support direct binding of mirabegron 117 to either the β1-AR or β2-AR, these findings lend further support to the mechanism whereby 118 mirabegron is taken up by sympathetic nerve terminals and then causes the release of 119 norepinephrine to bind to cardiac β1-AR's (21). Such cardiovascular stimulation is similar to 120 what we previously reported at 200 mg in men (7, 22) and demonstrates why dosages higher than 121 50 mg are not used clinically for overactive bladder. There was a diurnal variation in the change 122 in HR such that mirabegron increased HR more overnight than when the subjects were awake 123 and moving: +6.2 ± 1.7 bpm between 19:00-22:00 vs +8.4 ± 1.5 bpm between 00:00-03:00 (P < 124 0.001). None of the changes in HR or RPP correlated with the changes in REE (both P > 0.05, 125 not shown). Per self-administered questionnaires, 1-2 subjects reported occasionally 126 experiencing some of the anticipated mild treatment-emergent adverse effects (23): palpitations, 127 headaches, bowel habit changes, and tachycardia during exercise; none of these effects were 128 higher than Grade 1. The dose of mirabegron on Day 28 did not increase these cardiovascular 129 parameters any further. The changes were not long-lasting: two weeks after stopping treatment, 130 plasma mirabegron was 5.4 ± 0.1 nM, and heart rates returned to values at screening 131 (Supplemental Figure 6 ). Mirabegron treatment had no effect on exercise tolerance, with no 132 change in the maximal oxygen uptake (VO2max), maximum heart rate, or maximum wattage 
136
The effects of acute and chronic mirabegron treatment on plasma metabolites and hormones 137 could be separated into three distinct patterns (Supplemental Table 5 ). Most metabolites 138 demonstrated (A) no effect or changes resulting from fasting, independent of mirabegron.
139
However, one subset showed (B) acute increases on Day 28 that were blunted compared to Day Page 10 1: non-esterified fatty acids (NEFA) and β-hydroxybutyrate. Plasma level increases of these 141 metabolites was likely due to β3-AR stimulation of WAT. It remains to be determined whether 142 chronic mirabegron treatment led to reduced responsiveness by the WAT or if there was 143 increased consumption of the metabolites.
144
The final pattern (C) of metabolite changes in response to chronic mirabegron treatment has 145 the greatest potential to improve metabolic health. There were increased fasting levels of the 146 following: high-density lipoprotein (HDL) (+8%), ApoA1 (+12%), ApoE (+7%), total bile acids 147 (+49%), total GIP (+31%), and adiponectin (+35%). In addition, there was a reduction in the 148 ApoB100/ApoA1 ratio, a biomarker of cardiovascular risk (24). We found higher levels of both 149 total chenodeoxycholic acid (CDCA) (1003 ± 254 to 1641 ± 359 nM, P = 0.02) and the 150 unconjugated form (212 ± 64 to 542 ± 159 nM, P = 0.02), the latter of which may be able to 151 further boost BAT thermogenesis (25).
152
Without altering body weight, the initial clinical trials using non-FDA approved β3-AR 153 agonists provided some evidence for improved glucose tolerance (8) and insulin sensitivity (9).
154
In addition, rodent studies showed that β3-AR-mediated activation of WAT can increase 155 pancreatic β-cell insulin secretion (26-28). To assess both glucose metabolism and β-cell 156 function in our study using mirabegron, we performed frequently-sampled intravenous glucose 157 tolerance tests (FSIGT, Figure 5 Table 6 ) (29). Modeling showed that the parameters associated 159 with insulin sensitivity, insulin-independent glucose metabolism, and insulin secretion all 160 increased substantially ( Figure 5 , C-F). Whole body insulin sensitivity (SI), reflecting insulin's 161 action to both stimulate glucose uptake and suppress endogenous glucose production, increased 162 by 36% (P = 0.026). While SI includes insulin's actions to both stimulate glucose uptake and Page 11 suppress endogenous glucose production, the effects on tissue glucose uptake are dominant (30). 164 Glucose effectiveness (SG), the ability of glucose to mediate its own net disappearance 165 independent of elevated insulin response, increased by 34% (P = 0.002).
166
Regarding β-cell function, the acute insulin response to glucose (AIRG) increased by 37% (P 167 = 0.039). The Disposition Index (DI), an overall measure of the ability of β-cells to secrete 168 insulin when normalized to the degree of insulin resistance, increased by 82% (P = 0.005).
169
Despite the increases in both SI and AIRG, there was no relationship between the changes in 170 these two measures for each of the subjects (P = 0.39). The change in HOMA-IR, a measure of 171 insulin resistance (31) was not significant after chronic mirabegron treatment (0.09 ± 0.81, P = 172 0.72).
DISCUSSION

174
The labyrinthine paths toward developing pharmacological activators of β3-AR's and BAT 175 thermogenesis to treat human metabolic disease have much in common. Both have been 176 bolstered by decades of highly encouraging preclinical studies (4, 5, 8, 9), yet to date, neither has 177 achieved its goal. A major step forward for the β3-AR was the recent approval of mirabegron, 178 the first highly selective agonist, to treat overactive bladder (23). A single dose of mirabegron 179 stimulates BAT glucose uptake (22), a marker of thermogenesis, along with increases in WAT 180 lipolysis, REE, and changes in plasma bile acids (7). In this study, we report the physiological at much higher levels than scWAT and respond to treatment with adrenergic agonists by 190 increasing their thermogenic capacity. In addition, these dormant cells have less sympathetic 191 innervation, which could make them comparatively more responsive to pharmacological 192 activation through the blood than through cold exposure, which relies on sympathetic neurons. Besides effects on BAT, HDL cholesterol, and bile acids, mirabegron also produced 207 substantial improvements in glucose and insulin metabolism. In context, the increases we 208 observed in SG, SI, AIRG, and DI, between 30-90%, were generally in the range of interventions 209 associated with improvements in insulin sensitivity or pancreatic β-cell function: an acute dose 210 of iv GLP-1 (SI +4-29%, AIRG +48-66%) (42, 43); chronic metformin treatment in women with 211 polycystic ovary syndrome (SG +30%, SI +2.5%, AIRG +43%, DI +72%) (44); 9-15 months after 212 bariatric surgery (SI +116%, AIRG -56%) (45); and six weeks of mild exercise training in healthy 213 adults (SG +28%, SI +32%) (46). The improvements in glucose metabolism with mirabegron 214 treatment were not associated with changes in either fasting glucose or insulin. Similarly, iv 215 GLP-1 (42, 43) and exercise (46) did not raise or lower either fasting glucose or insulin levels, 216 while metformin lowered fasting glucose (44). Therefore, preliminary evidence suggests that mirabegron's effects on glucose metabolism, HDL cholesterol, and bile acids resemble those 218 achieved through mild exercise (47, 48).
219
As mentioned above, the changes in SI and AIRG were not correlated. This discordance may 220 have been because mirabegron likely affects insulin sensitivity and β-cell function via different 221 mechanisms that are not directly connected. One reason for significant improvements in SI and 222 SG, but not the HOMA-IR, may have been that the subjects here had near-normal HOMA-IR at 223 study initiation (1.75 ± 0.69), and HOMA-IR does not provide a precise estimate of peripheral 224 insulin action in this population (49). Any significant effects of mirabegron on glucose 225 metabolism would therefore likely be detected only when glucose homeostasis was strongly 226 perturbed, such as in the setting of the FSIGT (50, 51).
227
How mirabegron improved glucose metabolism is not known. Contributions could have 228 been from the higher plasma adiponectin (52), a WAT-derived adipokine that is associated with 229 higher insulin sensitivity in skeletal muscle (53) and liver (54). The elevated levels of the 230 incretin GIP can also improve glucose-stimulated insulin secretion (55). A third, parallel 231 mechanism may involve the β-cells themselves. While we did not detect β3-AR mRNA in 232 human islets (data not shown), there is evidence that WAT lipolysis (26, 27, 56) followed by 233 activation of β-cell fatty acid receptor GPR40, can stimulate insulin release (57). In summary, In conclusion, we demonstrated that chronic treatment for four weeks with the β3-AR agonist 252 mirabegron in healthy, young women with a range of BMI's led to increases in BAT metabolic 253 activity; REE; plasma HDL and associated lipoproteins; insulin sensitivity; and pancreatic β-cell 254 insulin secretion. These metabolic benefits occurred without changes in the subjects' weight, fat 255 mass, or lean body mass. Therefore, chronic activation of the β3-AR may be an effective way to 256 treat metabolic disease.
257
METHODS
258
Sample size calculation 259 Our previous studies showed that BAT activity was not normally distributed; rather, it is 260 right skewed (7, 22). Thus, our sample size determination was based on log10BAT activity.
261
Since there were no published studies assessing the effects of mirabegron on log10BAT activity, 262 we used a similar cohort exposed to chronic cold exposure (32) that reported changes in log10 263 BAT volume of +0.21 ± 0.25 mL. Since BAT volume correlates with BAT activity (12), we 264 then determined that a sample size of 14 female subjects was necessary to detect whether a 265 change in BAT metabolic activity was different from a null hypothesis of 0.00 with 80% power 266 using a paired Student's t-test with a significance level of 0.05 and a correlation (R) of 0.50.
267
Treatment was nonblinded for both staff and subjects. 62). Prior to 12:00 am, they were provided a high-carbohydrate, high-protein snack that was 251 304 ± 49 kcal. Inpatient rooms were kept at 24 °C, and subjects were asked to go to sleep at the same 305 time each night. Clothing was standardized during each metabolic chamber stay as described 306 (12).
307
Subjects fasted from 00:00 until completing testing later that day (Day 0/Day 27). Subjects 308 first underwent a frequently-sampled intravenous glucose tolerance test (FSIGT) from 08:00- Mar-Reynolds, Irvine, CA, USA). Energy expenditure and RQ were calculated for the entire 20-328 hour chamber stay, and the first and last 30 minutes were excluded in determining the overall 329 energy expenditure and RQ. At 18:00, they were provided an isocaloric dinner and snack; they 330 fasted from 00:00 until exiting the chamber the following day (Day 1/Day 28). Thirteen of 14 331 enrolled subjects completed the full overnight stay in the metabolic chambers. One subject 332 entered the metabolic chamber at 08:00 on Day 1/28 instead of 18:00 the prior night because of 333 scheduling constraints. Heart rate, and blood pressure, were determined as described (7, 63).
334
Core temperature was measured by the participant using a handheld infrared tympanic 335 thermometer (PRO4000, Braun, Melsungen, Germany).
336
The relative humidity of each chamber was controlled between 30-50%. The chamber's 337 temperature was set to 26 °C to ensure that BAT was not activated by cold exposure. While in 338 the chamber, subjects were asked to minimize their physical activity and stay awake other than 339 during their nightly sleep period. Sleep actigraphy was measured using triaxial accelerometers 340 (Actigraph GT3X+, Actigraph LLC, Pensacola, FL) worn on the wrist. We used the Kripke algorithm implemented in ActiLife software (version 6.12.0) to detect time-in-bed, sleep 342 onset, and awakenings and recorded total minutes in bed, total sleep time, and sleep efficiency, 343 which is the ratio of the two (64).
344
Between 08:25-08:55 and 13:10-13:40, volunteers sat upright and still, without any physical 345 activity. These inactive periods provided motion-free data to calculate REE and resting heart 346 rate. Study subjects were administered 100 mg mirabegron at 09:00 (+0 minutes). Blood 347 samples used to measure blood metabolites were obtained 60 minutes prior to mirabegron dosing 348 (08:00) and then 60 minutes prior to exiting the metabolic chamber (13:00). Blood samples used to test for plasma mirabegron concentrations were obtained at +0, +30, +60, +120, +180, +210, Specific CT density ranges were used to identify fat (-300 to -10 HU) from air and other tissues. 
363
BAT metabolic activity, defined as BAT volume multiplied by SUV mean, where SUV mean 364 is the average radioactivity concentration in BAT divided by injected FDG dose per body 365 weight. It, along with BAT volume; BAT, skeletal muscle, and scWAT SUVmax; and gallbladder 366 volume were quantified as previously described (7, 12, 65): one ROI was created on each axial 367 slice, avoiding regions that were not metabolically active fat in order to minimize false-positive 368 detection. ROI selection began at the slice corresponding to vertebra C3 and continued inferiorly 369 until the umbilicus. All axial ROIs were summed to calculate total body BAT volume and 370 activity, and SUVs were averaged to determine the SUVmean. The study parameters have also Islets from previously non-diabetic or type 2 diabetic human cadaver donor pancreases were 416 obtained via the NIDDK-sponsored Integrated Islet Distribution Program (Duarte, CA) as 417 described (68). mRNA was extracted and quantified via qPCR as described (7). , dual-energy X-ray absorptiometry (DXA), then entered the metabolic chamber at 18:00 and remained overnight and through 14:00 of Day 1/Day 28, after which they were transported to the PET/CT suite. Blood was drawn to measure metabolites before treatment on Day 1/Day 28 at 08:00 and then just prior to 18 F-FDG administration in the chamber at 13:00. Mirabegron was administered at 09:00. The black bars above the diagrams refer to the 30-minute still periods at which resting energy expenditure (REE) was measured. The black arrows indicate the time points at which blood was drawn for pharmacokinetic measurements. 
